Vertex reports Q3 2026 revenue beat and lifts full‑year guidance
Vertex Pharmaceuticals posted third‑quarter 2026 revenue of $3.44 billion, up about 12% year‑over‑year, and adjusted earnings per share of $4.76, matching consensus. The company raised its full‑year 2026 revenue guidance to a range of $13.15 billion‑$13.25 billion, up from $13.10 billion‑$13.20 billion. The results were driven by strong sales of newer cystic‑fibrosis drug Alyftrek and rapid growth in non‑CF products such as CASGEVY and JOURNAVX, while the Crinetics acquisition added a new endocrine‑disease pillar.
Why it matters
The higher revenue outlook signals continued top‑line growth, which may support the stock price and affect analysts’ target models (the company noted the guidance raise). The guidance still falls slightly below consensus, indicating modest upside for investors.
Key facts
- 1Q3 2026 revenue was $3.44 billion, up 12% YoY. grafa.com
- 2Adjusted EPS for Q3 2026 was $4.76 per share. investing.com
- 3Full‑year 2026 revenue guidance was raised to $13.15 billion‑$13.25 billion. grafa.com
- 4The prior guidance range was $13.10 billion‑$13.20 billion. investing.com
- 5Alyftrek generated $706 million in Q3 revenue. fool.com
- 6CASGEVY revenue was $99 million, a 30% quarter‑over‑quarter increase. investing.com
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.